Clinical medicine profile
Ilaprazole
Proton pump inhibitor (PPI)
- Route
- ORAL / IV
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to PPIs.
- Caution with rilpivirine and some antivirals (gastric pH).
Precautions
- Use lowest effective dose/shortest duration.
- Long-term: hypomagnesaemia, B12 deficiency, increased GI infection risk, fracture signal, fundic polyps.
- Masking of malignancy — investigate alarm features.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Rare AIN; otherwise minimal renal dosing issues.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Severe hepatic impairment: dose reduction for some agents.
Use, effects & interactions
Indications
- Duodenal ulcers, benign gastric ulcers, and prevention of peptic ulcers associated with NSAIDs, reflux oesophagitis, Zollinger-Ellison syndrome Clinical selection for Ilaprazole should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Proton pump inhibitor (PPI).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Candidiasis, GI disturbances, skin rashes, photosensitivity, stomatitis blood dyscrasia, hypersensitivity, CNS effects, paraesthesia, malaise, alopecia, muscle weakness, myalgia, peripheral edema, gynecomastia, hepatitis.
Drug interactions
Open multi-drug checker ↗- Step-down after healing peptic disease.
- Test-and-treat or empiric strategies per local dyspepsia pathways.
- Review chronic PPI prescriptions for deprescribing eligibility.
Mechanism & disposition
PPIs irreversibly inhibit the gastric H+/K+-ATPase (proton pump) in parietal cells, suppressing basal and stimulated acid secretion — the most potent pharmacological acid suppression.
Read complete mechanism
PPIs irreversibly inhibit the gastric H+/K+-ATPase (proton pump) in parietal cells, suppressing basal and stimulated acid secretion — the most potent pharmacological acid suppression.
1–2 hours; full acid suppression days
24 hours+ (irreversible pump inhibition)
ORAL / IV
(polymorphisms affect levels). Short plasma
but prolonged pharmacodynamic effect.
Pregnancy, lactation & diet
Often used when indicated; omeprazole has substantial human data — still risk–benefit.
Generally considered acceptable; infant exposure low.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| ILAPRAZ | DAIMA BIASHARA / Wholesale Import | 10MG 10*S | KES 598.09daima_biashara_price_list |
| ILAPRAZ-20 | GALAXY PHARMACEUTICAL LIMITED | Film-Coated Tablet | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.